Kymanox Launched Searchable Drug Delivery Platform
The new KymaBridge portal centralizes technical data for autoinjectors and other drug-delivery devices.
Updated on Oct. 5, 2026 in Biotech
Live Poll
Do you believe centralized digital platforms effectively accelerate the development of new pharmaceutical products?
Kymanox has launched KymaBridge, an online platform designed to provide centralized technical information on drug delivery devices. The platform includes verified data on technologies ranging from prefilled syringes to on-body injectors.
Why it matters
Pharmaceutical sponsors currently struggle to aggregate fragmented technical documentation for regulated devices. This platform attempts to resolve those supply chain visibility gaps by providing data that is both independent-expert reviewed and supplier-confirmed.
The database covers six categories including autoinjectors, pen injectors, on-body injectors, nasal devices, inhalers, and prefilled syringes. Information is curated through a multi-step process combining independent expert review with direct confirmation from the device suppliers.
The players
Kymanox
A technical services provider with two decades of experience in the development of drug-device combination products.
The details
KymaBridge addresses the administrative friction in drug-device combination products, which are specialized medical items that combine a drug with a delivery mechanism. The platform functions as a searchable repository where suppliers can manage their own profile pages to update technical specifications. A paid Prime membership tier provides extra functionality, allowing these suppliers to access granular usage reports on who is viewing their specific device data.
Timeline
October 05, 2026: Kymanox announced the official launch of the KymaBridge platform.
Over the next year: Kymanox intends to advance and expand the platform's features and offerings.
The Tech Race
The launch marks a move toward digitizing the complex vendor-matching process for regulated medical components. By building a centralized verification system, Kymanox positions itself against informal, scattered procurement methods that historically define the medical device supply chain.
Pharmaceutical developers and device engineers can now access the database to streamline their technical research and device selection processes. Suppliers interested in professional-tier access for profile management and data analytics can sign up immediately via the company's portal.
The takeaway
Centralizing technical device data reduces the regulatory risk associated with missing or poorly verified documentation. Watch for the platform’s expansion in the coming year to see if it becomes a standard registry for prefilled syringe and injector specifications across the pharmaceutical industry.
Further reading
For more on how digital infrastructure is modernizing life sciences development, see our Biotech section.
More information
To explore the available device technical data or register as a supplier, visit the KymaBridge platform registration.
Live Poll
Do you believe centralized digital platforms effectively accelerate the development of new pharmaceutical products?
